3Tumer RC,Millns,Neil H,et al.For the united kingdom prospective diabetes study group.Risk factors for coronary artery disease in non-in-sulin dependent diabetes mellitus:united kingdom prospective diabetes study(UKPDS:23)[J].BMJ,1998,316:823.
4Gami AS,Montori VM,Erwin PJ,et al.Systematic review of lipid lowering for primary prevention of coronary heart diease in diabetes[J].BMJ,2003,326(7388):528-529.
二级参考文献7
1Luc G. Mechanisms of action of hypolipidemic agents,Therapie 2000 ; 55 (6) : 661 - 668.
2Chinetti G, Fruchart JC, Staeles B, Peroxisome prolifera-toractivated receptors(PPARs): nuclear receptors with functions in the vascular wall, Z Kardiol 2001;90 Suppl 3:125-132.
3Steinmez A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001 ; 109(4) :548- 559.
4Rubbins H B, Roins S J, Collins D, et al. Gemfibrozil for the second prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group,NEngl J Med 1999;341:410-418.
5Goa K L, Barradell L B, Plosker G L, Bezafibrate, and update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52(5) :725-753.
6Frick M H, Syvanne M, Nieminen M S, et al. Prevention of angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation 1997;96:2137-2143.
7Diabetes atherosclerosis Intervention Study Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Dlabetes atherosclerosis Intervention Study,a radomized studies. Lancet 2001 ; 357 : 905- 910.